GastroEsophageal Cancer New Reference: NOTCH1 Mutation as a Predictive Marker for Tislelizumab Ulas D. Bayraktar, MD 2025-04-22
Diffuse Large B Cell Lymphoma New Protocol: Brentuximab-Rituximab-Lenalidomide for Large Cell Lymphoma Ulas D. Bayraktar, MD 2025-04-07
Multiple Myeloma New Reference: Talquetamab for Relapsed/Refractory Multiple Myeloma Ulas D. Bayraktar, MD 2025-04-07
Pancreatic Cancer New Reference: Neoadjuvant FOLFIRNOX for Pancreatic Cancer Ulas D. Bayraktar, MD 2025-04-07
Renal Cell Carcinoma New Reference: Ipilimumab / Nivolumab for Non-Clear Cell RCC Ulas D. Bayraktar, MD 2025-04-07
Bladder Cancer New Reference: Sacituzumab Govitecan for Advanced Urothelial Carcinoma Ulas D. Bayraktar, MD 2025-04-07
Colorectal Cancer New Reference: Encorafenib, Cetuximab, Chemotherapy in bRAF Mutant Colorectal Cancer Ulas D. Bayraktar, MD 2025-03-31
Bladder Cancer New Indication: Adjuvant Pembrolizumab for Bladder Cancer Ulas D. Bayraktar, MD 2025-03-31
Non-Small Cell Lung Cancer New Indication: Datopotamab Deruxtecan in NSCLC with Actionable Mutations Ulas D. Bayraktar, MD 2025-03-31
